Publications

Title

Author

Year

Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.

Novaes, HM D; De Soárez, PC; Silva, GA; Ayres, A; Itria, A; Rama, CH; Sartori, AM C; CLARK, AD; Resch, S;

2014

Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.031.

Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.

Komakhidze, T; Hoestlandt, C; Dolakidze, T; Shakhnazarova, M; Chlikadze, R; Kopaleishvili, N; Goginashvili, K; Kherkheulidze, M; CLARK, AD; Blau, J;

2014

Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.070.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina, VV; Filipović, SK; Kožnjak, N; Stamenić, V; CLARK, AD; Mounaud, B; Blau, J; Hoestlandt, C; Kaić, B;

2014

Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.043.

Impaired natural killer cell responses to vaccine antigens in human cytomegalovirus-infected individuals.

Nielsen, CM; White, MJ; Rodriguez-Galan, A; BOTTOMLEY, C; Turner, SE G; GOODIER, MR; Riley, EM;

2014

IMMUNOLOGY, (2014).143,

Serological screening of six soluble Chlamydia trachomatis antigens for use in trachoma candidate vaccine studies.

Pickering, H; Tetteh, K; Hayward, RD; HOLLAND, MJ;

2014

IMMUNOLOGY, (2014).143,

Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.

Wakeham, K; Johnston, WT; NALWOGA, A; WEBB, EL; Mayanja, BN; Miley, W; ELLIOTT, AM; Whitby, D; NEWTON, R;

2014

International journal of cancer Journal international du cancer, (2014).136 12 10.1002/ijc.29329.

Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.

LARSON, HJ; WILSON, R; Hanley, S; Parys, A; PATERSON, P;

2014

Human vaccines & immunotherapeutics, (2014).10 9 10.4161/21645515.2014.969618.

CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Musson, JA; Reynolds, CJ; Rinchai, D; Nithichanon, A; Khaenam, P; Favry, E; SPINK, N; Chu, KK Y; De Soyza, A; BANCROFT, GJ; Lertmemongkolchai, G; Maillere, B; Boyton, RJ; Altmann, DM; Robinson, JH;

2014

Journal of immunology (Baltimore, Md, (2014).193 12 10.4049/jimmunol.1402273.

Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Newall, AT; JIT, M; Hutubessy, R;

2014

PharmacoEconomics, (2014).32 12 10.1007/s40273-014-0232-0.

Vaccine-preventable travel health risks: what is the evidence--what are the gaps?.

Steffen, R; BEHRENS, RH; Hill, DR; Greenaway, C; Leder, K;

2014

Journal of travel medicine, (2014).22 1 10.1111/jtm.12171.